Perfluorocarbon nanoparticles: A theranostic platform technology

Gregory M. Lanza; Patrick M. Winter; Shelton D. Caruthers; Michael S. Hughes; Grace Hu; Dipanjan Pan; Anne H. Schmieder; Christine Pham; Samuel A. Wickline

doi:10.1142/9789814368674_0012

Perfluorocarbon nanoparticles: A theranostic platform technology

Gregory M. Lanza, Patrick M. Winter, Shelton D. Caruthers, Michael S. Hughes, Grace Hu, Dipanjan Pan, Anne H. Schmieder, Christine Pham, Samuel A. Wickline

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Nanomedicine clearly offers unique tools to address intractable medical problems in cancer and cardiovascular disease from entirely new perspectives. Among the theranostic options emerging in this new wave of biotechnology development, the perfluorocarbon nanoparticles have shown robust potential in vivo for diagnosing, characterizing, treating and following proliferating cancers, progressive atherosclerosis, rheumatoid arthritis and much more. These molecular imaging agents have been demonstrated for use with ultrasound, MRI, CT, and SPECT/CT. Moreover, the synergism of imaging for confirmation of therapeutic delivery, for dosimetry, and for noninvasively following early treatment responses is discussed. Image-guided drug delivery based on nanotechnology is emerging as a powerful clinical opportunity, and PFC nanoparticles are among the leading technologies reaching clinical testing today with this potential.

Original language	English (US)
Title of host publication	Nanopharmaceutics
Subtitle of host publication	The Potential Application of Nanomaterials
Publisher	World Scientific Publishing Co.
Pages	293-346
Number of pages	54
ISBN (Electronic)	9789814368674
ISBN (Print)	9789814368667
DOIs	https://doi.org/10.1142/9789814368674_0012
State	Published - Jan 1 2012

All Science Journal Classification (ASJC) codes

General Biochemistry, Genetics and Molecular Biology
General Engineering
General Medicine
General Health Professions

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1142/9789814368674_0012

Cite this

@inbook{28dd1dac930c409c81bafc77576b8a9d,

title = "Perfluorocarbon nanoparticles: A theranostic platform technology",

abstract = "Nanomedicine clearly offers unique tools to address intractable medical problems in cancer and cardiovascular disease from entirely new perspectives. Among the theranostic options emerging in this new wave of biotechnology development, the perfluorocarbon nanoparticles have shown robust potential in vivo for diagnosing, characterizing, treating and following proliferating cancers, progressive atherosclerosis, rheumatoid arthritis and much more. These molecular imaging agents have been demonstrated for use with ultrasound, MRI, CT, and SPECT/CT. Moreover, the synergism of imaging for confirmation of therapeutic delivery, for dosimetry, and for noninvasively following early treatment responses is discussed. Image-guided drug delivery based on nanotechnology is emerging as a powerful clinical opportunity, and PFC nanoparticles are among the leading technologies reaching clinical testing today with this potential.",

author = "Lanza, {Gregory M.} and Winter, {Patrick M.} and Caruthers, {Shelton D.} and Hughes, {Michael S.} and Grace Hu and Dipanjan Pan and Schmieder, {Anne H.} and Christine Pham and Wickline, {Samuel A.}",

year = "2012",

month = jan,

day = "1",

doi = "10.1142/9789814368674_0012",

language = "English (US)",

isbn = "9789814368667",

pages = "293--346",

booktitle = "Nanopharmaceutics",

publisher = "World Scientific Publishing Co.",

address = "United States",

}

TY - CHAP

T1 - Perfluorocarbon nanoparticles

T2 - A theranostic platform technology

AU - Lanza, Gregory M.

AU - Winter, Patrick M.

AU - Caruthers, Shelton D.

AU - Hughes, Michael S.

AU - Hu, Grace

AU - Pan, Dipanjan

AU - Schmieder, Anne H.

AU - Pham, Christine

AU - Wickline, Samuel A.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Nanomedicine clearly offers unique tools to address intractable medical problems in cancer and cardiovascular disease from entirely new perspectives. Among the theranostic options emerging in this new wave of biotechnology development, the perfluorocarbon nanoparticles have shown robust potential in vivo for diagnosing, characterizing, treating and following proliferating cancers, progressive atherosclerosis, rheumatoid arthritis and much more. These molecular imaging agents have been demonstrated for use with ultrasound, MRI, CT, and SPECT/CT. Moreover, the synergism of imaging for confirmation of therapeutic delivery, for dosimetry, and for noninvasively following early treatment responses is discussed. Image-guided drug delivery based on nanotechnology is emerging as a powerful clinical opportunity, and PFC nanoparticles are among the leading technologies reaching clinical testing today with this potential.

AB - Nanomedicine clearly offers unique tools to address intractable medical problems in cancer and cardiovascular disease from entirely new perspectives. Among the theranostic options emerging in this new wave of biotechnology development, the perfluorocarbon nanoparticles have shown robust potential in vivo for diagnosing, characterizing, treating and following proliferating cancers, progressive atherosclerosis, rheumatoid arthritis and much more. These molecular imaging agents have been demonstrated for use with ultrasound, MRI, CT, and SPECT/CT. Moreover, the synergism of imaging for confirmation of therapeutic delivery, for dosimetry, and for noninvasively following early treatment responses is discussed. Image-guided drug delivery based on nanotechnology is emerging as a powerful clinical opportunity, and PFC nanoparticles are among the leading technologies reaching clinical testing today with this potential.

UR - http://www.scopus.com/inward/record.url?scp=84973468825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973468825&partnerID=8YFLogxK

U2 - 10.1142/9789814368674_0012

DO - 10.1142/9789814368674_0012

M3 - Chapter

AN - SCOPUS:84973468825

SN - 9789814368667

SP - 293

EP - 346

BT - Nanopharmaceutics

PB - World Scientific Publishing Co.

ER -

Perfluorocarbon nanoparticles: A theranostic platform technology

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this